{"id":"W3208635967","doi":"10.1016/j.htct.2021.10.331","title":"EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA","year":2021,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Institute of Cancer Research; McGill University Health Centre; University of Calgary","funders":"","keywords":"Medicine; Cytokine release syndrome; Common Terminology Criteria for Adverse Events; Adverse effect; Multiple myeloma; Neutropenia; Internal medicine; Gastroenterology; Oncology; Toxicity; Chimeric antigen receptor; Immunology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008822659,0.0005069639,0.001242754,0.0002877152,0.000250022,0.0004376389,0.0002854924,0.0004585139,0.0009483411],"category_scores_gemma":[0.0006491928,0.0002624885,0.001022036,0.0003047289,0.0004822352,0.0005338811,0.0002358091,0.001505376,0.0003382997],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007866106,"about_ca_system_score_gemma":0.000584682,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007336927,"about_ca_topic_score_gemma":0.001106632,"domain_scores_codex":[0.999663,0.0001285756,0.00002618317,0.00006454923,0.00006229291,0.00005530633],"domain_scores_gemma":[0.9996946,0.00005951451,0.00008738286,0.00002727404,0.00001696328,0.0001143463],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3999779,0.02257154,0.04110073,0.0008674325,0.001442078,0.0006848095,0.0004489014,0.007232124,0.07838609,0.000284369,0.003192133,0.4438119],"study_design_scores_gemma":[0.1127514,0.6477837,0.2065881,0.00009498882,0.001576126,0.001584835,0.00009395786,0.006493032,0.0149488,0.0004097452,0.007582033,0.00009325272],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938232,0.00389472,0.0003468082,0.0001657338,0.00003323041,0.000177583,0.000356029,0.00005091048,0.001151869],"genre_scores_gemma":[0.997568,0.000922756,0.0002676934,0.0001770306,0.00004951372,0.0000886013,0.0004392054,0.000006367915,0.0004809666],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001242754,"threshold_uncertainty_score":0.005707324,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01486742412468083,"score_gpt":0.2713815356584001,"score_spread":0.2565141115337193,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}